This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.



Drug Names(s): PYM50028, P58 (PD), P63 (AD)

Description: Cogane belongs to a family of compounds called sapogenins, and is thought to induce the production of neurotrophic factors. It has reduced parkinsonian disability by 43% in a gold standard macaque model of Parkinson Disease.

Deal Structure: Phytopharm and Yamanouchi
On May 1, 2003, Phytopharm signed a licensing agreement with Yamanouchi Pharmaceutical Co., Ltd., for the development and commercialisation of Cogane. Under this agreement, Yamanouchi acquired an exclusive license to develop, manufacture and market Cogane in Japan and some other Asian countries. Phytopharm received $3 million immediately, followed by a further five milestones totalling $17 million payable over two years, subject to the achievement of specific objectives. In total, Phytopharm is entitled to $33 million of license fees and potential milestone payments with respect to the Alzheimer's indication. Yamanouchi also acquired the option to license Cogane for additional indications for which further details of these fees and milestones are are not disclosed. Phytopharm will also receive royalties on sales of Cogane by Yamanouchi for all indications developed.

Yamanouchi and Astellas
In April 2005, Astellas Pharma was formed...See full deal structure in Biomedtracker

Partners: Astellas Pharma, Inc.

Cogane News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug